Name of opportunity: 👀
Denali Therapeutics Inc
Rising after FDA breakthrough status ✅
Denali Therapeutics Inc is up by 14.73% in the past day, and 5.08% in the past week. This might be because the company recently received FDA breakthrough status on tividenofusp alfa, an enzyme replacement therapy to help treat Hunters syndrome, a rare genetic disorder.
Denali Therapeutics is classified as a growth stock, meaning it reinvests profits for future growth. Analysts are currently calling this stock a ‘Strong Buy’ - meaning now might be a good time to invest!
How hot is this investment opportunity? 🔥🔥🔥
Analysts predict the price of Denali Therapeutics Inc might increase from $21.50 to $39.60 in the next 12 months. If you invested $1000, you might profit $841.86.
Earning FDA Breakthrough Therapy Designation is very beneficial for a biotech company, as it can speed up the development and regulatory review of important therapies. Denali Therapeutics recently earning FDA breakthrough status means that tividenofusp alfa is closer to being launched in the future and available for sale.
Another positive effect of receiving FDA breakthrough status is that it validates the drug's potential, which showcases innovation, and which could therefore boost investor confidence. Additionally, it gives the company a competitive edge when it comes to the development of therapies in this area.
The company is also developing a therapy called DNL-126 for Sanfilippo syndrome, with other key developments in progress too. This might indicate future success for the company.
Biopharmaceutical company 🧪
Denali Therapeutics Inc is a biotechnology company that focuses on the development of therapies for those with neurodegenerative diseases. The company is headquartered in San Francisco, California, United States.
Which neme?: 🔍
‘Top Gainers Today’, ‘Stocks On The Move’.
Download Nemo Money to check out Denali Therapeutics Inc. New users can grab our registration bonus up to a maximum of $50 on first deposit. Terms and conditions apply.
